Needham Maintains Buy Rating on Collegium Pharmaceutical, Lowers Price Target
Needham & Company maintained its 'Buy' rating on Collegium Pharmaceutical while adjusting its price target from $46 to $44.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Needham & Company maintained its 'Buy' rating on Collegium Pharmaceutical while adjusting its price target from $46 to $44.
Collegium Pharmaceutical (NASDAQ:COLL) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by
Collegium Pharmaceutical announced its financial results for the third quarter ended September 30, 2026, and reaffirmed its full-year 2026 financial guidance.
Filed: 2026-11-05 AccNo: 0001628280-26-070585 Size: 3 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Collegium Pharmaceutical has expanded its partnership with Boston Legacy FC to include community-based programming across Massachusetts, ahead of the company's planned headquarters relocation to Boston in 2027.
Collegium Pharmaceutical and Boston Legacy FC announced an expanded multi-year partnership to support neurodivergent children and families across Massachusetts. The partnership includes a soccer coaching certification initiative to train coaches in supporting children with ADHD, an annual Sports for All Summit, and continued sensory inclusion programs. Collegium will also increase its presence as an Official Partner with branding on Boston Legacy FC's game kits and stadium signage ahead of its headquarters move to Boston in early 2027.